Pyxis Oncology, Inc. (NASDAQ:PYXS) Receives $6.83 Average Target Price from Brokerages

Shares of Pyxis Oncology, Inc. (NASDAQ:PYXS) have earned a consensus recommendation of “Moderate Buy” from the nine brokerages that are presently covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have given a buy rating to the company. The average 12-month price target among analysts that have covered the stock in the last year is $6.8571.

PYXS has been the subject of several recent analyst reports. Weiss Ratings downgraded Pyxis Oncology from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday. Leerink Partners lowered their target price on shares of Pyxis Oncology from $9.00 to $7.00 and set an “outperform” rating for the company in a research note on Thursday. HC Wainwright reiterated a “buy” rating and set a $7.00 price target on shares of Pyxis Oncology in a research report on Tuesday, March 24th. Wedbush started coverage on shares of Pyxis Oncology in a report on Tuesday, May 5th. They issued an “outperform” rating and a $6.00 price objective on the stock. Finally, Wall Street Zen downgraded Pyxis Oncology from a “hold” rating to a “sell” rating in a research report on Saturday, May 16th.

Hedge Funds Weigh In On Pyxis Oncology

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Maia Wealth LLC bought a new position in shares of Pyxis Oncology in the fourth quarter valued at approximately $25,000. Engineers Gate Manager LP acquired a new stake in shares of Pyxis Oncology during the fourth quarter worth $26,000. Fox Run Management L.L.C. purchased a new stake in Pyxis Oncology during the fourth quarter valued at about $26,000. Avanza Fonder AB purchased a new stake in shares of Pyxis Oncology in the 4th quarter valued at approximately $31,000. Finally, XTX Topco Ltd acquired a new stake in shares of Pyxis Oncology in the second quarter worth $40,000. Institutional investors own 39.07% of the company’s stock.

Pyxis Oncology Trading Down 7.7%

Shares of Pyxis Oncology stock opened at $2.63 on Friday. Pyxis Oncology has a twelve month low of $0.97 and a twelve month high of $5.55. The company has a fifty day moving average price of $2.04 and a 200 day moving average price of $1.73. The stock has a market cap of $166.61 million, a price-to-earnings ratio of -2.01 and a beta of 1.30.

Pyxis Oncology (NASDAQ:PYXS) last announced its earnings results on Thursday, May 14th. The company reported ($0.37) EPS for the quarter, missing the consensus estimate of ($0.35) by ($0.02). Analysts forecast that Pyxis Oncology will post -1.23 earnings per share for the current year.

Pyxis Oncology Company Profile

Pyxis Oncology (NASDAQ: PYXS) is a clinical‐stage biotechnology company focused on the discovery and development of targeted oncology therapies. The company’s platform centers on antibody‐drug conjugates (ADCs) that deliver potent mitotic inhibitors directly to cancer cells, leveraging novel payloads designed to disrupt cell division. By combining highly specific antibodies with innovative cytotoxic agents, Pyxis Oncology aims to improve therapeutic windows and reduce off‐target toxicities common to conventional chemotherapies.

Since its inception, Pyxis Oncology has built a pipeline of early‐stage ADC candidates directed against a variety of solid tumor antigens.